JCCVS
Journal of Cardiology & Cardiovascular Surgery

Journal of Cardiology & Cardiovascular Surgery scientific, open-access, double-blind peer-reviewed journal covering a wide spectrum of topics in cardiology and cardiovascular surgery.

eISSN: 2980-1397
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
Clinical approach and emerging therapies for elevated lipoprotein(a): current evidence and guideline-based recommendations
Abstract
Elevated lipoprotein(a) [Lp(a)] is an independent, genetically determined, and causally associated risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic-valve stenosis. Approximately one in four adults worldwide have elevated Lp(a) levels (>= 50 mg/dL or >= 125 nmol/L), conferring substantial residual risk even in the setting of optimal low-density lipoprotein cholesterol (LDL-C) control. Traditional lipid-lowering therapies exert minimal impact on Lp(a); however, recent breakthroughs with antisense oligonucleotides (ASO) and small-interfering RNA (siRNA) therapeutics have demonstrated reductions exceeding 90 %. This review summarises the clinical implications of elevated Lp(a), highlights ongoing and emerging therapeutic trials, and integrates current recommendations from international guidelines. Lp(a) testing should become an integral part of cardiovascular risk assessment, and novel therapies are poised to redefine lipid management strategies in the near future. However, despite major advances, significant gaps remain in screening strategies, assay standardisation, and the long-term clinical impact of emerging Lp(a)-targeted therapies.

Keywords : Lipoprotein(a), cardiovascular risk, aortic valve stenosis, antisense oligonucleotides, sirna therapy

Download Article


1. Tsimikas S, Stroes ESG. The dedicated “Lp(a) clinic”: a concept whose time has arrived? Atherosclerosis. 2020;300:1-9. doi:10.1016/j.atherosclerosis.2020.03.003
2. Kronenberg F, Mora S, Stroes ESG, et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023;374:107-120. doi:10.1016/j.atherosclerosis.2023.04.012
3. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339. doi:10.1001/jama.2009.801
4. Kamstrup PR. Lipoprotein(a) and cardiovascular disease. Clin Chem. 2021;67(1):154-166. doi:10.1093/clinchem/hvaa247
5. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361(26):2518-2528. doi:10.1056/NEJMoa0902604
6. Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388(10057):2239-2253. doi:10.1016/S0140-6736(16)31009-1
7. O’Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022; 387(21):1855-1864. doi:10.1056/NEJMoa2211023
8. O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483-1492. doi:10.1161/CIRCULATIONAHA.118.037184
9. Koschinsky ML, Soffer DE, Boffa MB. What’s next for lipoprotein(a)? A National Lipid Association report from an Expert Panel Discussion. J Clin Lipidol. 2024;18(6):e886-e892. doi:10.1016/j.jacl.2024.06.005
10. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
11. Greco A, Finocchiaro S, Spagnolo M, et al. Lipoprotein(a) as a pharmacological target: premises, promises, and prospects. Circulation. 2025;151(6):400-415. doi:10.1161/CIRCULATIONAHA.124.069210
12. Doherty S, Hernandez S, Rikhi R, et al. Lipoprotein(a) as a causal risk factor for cardiovascular disease. Curr Cardiovasc Risk Rep. 2025;19:8. doi:10.1007/s12170-025-00760-1
13. Nordestgaard BG, Chapman MJ, Ray KK, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853. doi:10.1093/eurheartj/ehq386
14. Nasrallah N, Atallah M, Harb T, et al. Lipoprotein(a) in clinical practice: risk stratification and therapeutic strategies. Eur J Clin Invest. 2025;e70127. doi:10.1111/eci.70127
15. Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619-627. doi:10.1001/jamacardio.2018.1470
16. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013; 368(6):503-512. doi:10.1056/NEJMoa1109034
17. Gelfert GG, Grittner U, Kuhnert R, et al. Association of lipoprotein(a) with cardiovascular and cerebrovascular disease in a nationally representative cohort of Germany. JACC Adv. 2025;4(8):102015. doi:10. 1016/j.jacadv.2025.102015
18. Athauda-Arachchi PM, Kaththiriarachchi L, Salgado W, et al. Cross-sectional study of lipoprotein(a) and the severity of coronary artery disease, cerebrovascular disease, and peripheral vascular disease in a group of South Asian patients. Cardiovasc Endocrinol Metab. 2025; 14(2):e00327. doi:10.1097/XCE.0000000000000327
19. Xu R, Wang Z, Dong J, et al. Lipoprotein(a) and panvascular disease. Lipids Health Dis. 2025;24(1):186. doi:10.1186/s12944-025-02600-y
20. Paragh G, Zilahi P, Kolozsvári LR, Lorincz H, Fülöp P, Harangi M. Novel therapeutic approaches for the management of elevated lipoprotein(a): from traditional agents to future treatment options. Life (Basel). 2024;14(3):374. doi:10.3390/life14030374
21. Wodaje T, Mahdi A, Venkateshvaran A, et al. Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia. Atherosclerosis. 2024;389:117439. doi:10.1016/j.atherosclerosis.2023.117439
22. Awad K, Farina JM, Sheashaa H, et al. Reevaluating lipoprotein(a) levels and risk of all-cause mortality: a retrospective cohort study. Eur J Prev Cardiol. 2025. doi:10.1093/eurjpc/zwaf700
23. Loh WJ, Thai L, Poon BL, et al. Barriers and strategies in detection and management of elevated lipoprotein(a) in hospital: a pre-implementation qualitative study of cardiology healthcare professionals. PLoS One. 2025;20(10):e0333789. doi:10.1371/journal.pone.0333789
24. Razavi AC, Reyes MP, Wilkins JT, et al. Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a). Eur J Prev Cardiol. 2025;32(9):724-732. doi:10.1093/eurjpc/zwae382
25. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. doi:10.1056/NEJMoa 1107579
26. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212. doi:10.1056/NEJMoa1300955
27. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on blood cholesterol management. J Am Coll Cardiol. 2019;73(24): e285-e350. doi:10.1016/j.jacc.2018.11.003
28. Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical trial design for lipoprotein(a)-lowering therapies: JACC Focus Seminar 2/3. J Am Coll Cardiol. 2023;81(16):1633-1645. doi:10.1016/j.jacc.2023.02.033
29. Ruscica M, Greco MF, Ferri N, Corsini A. Lipoprotein(a) and PCSK9 inhibition: clinical evidence. Eur Heart J Suppl. 2020;22(Suppl L): L53-L56. doi:10.1093/eurheartj/suaa135
30. Cho L, Nicholls SJ, Nordestgaard BG, et al. Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a). Am Heart J. 2025;287:1-9. doi:10.1016/j.ahj.2025.03.019
31. Kaur G, Rosenson RS, Gencer B, et al. Olpasiran lowering of lipoprotein(a) according to baseline levels: OCEAN(a)-DOSE insights. Eur Heart J. 2025;46(12):1162-1164. doi:10.1093/eurheartj/ehae781
32. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190
Article available in :
Volume 3, Issue 4, 2025
Page : 82-86
https://doi.org/10.51271/JCCVS-0065
Article Information
Received : 16 Kas 2025
Accepted : 20 Ara 2025
Published : 23 Ara 2025
Corresponding Author :

Ramazan Astan: Department of Cardiology, Batman Training and Research Hospital, Batman, Turkiye

[email protected]
Citation : Astan R, Sarıçam E, Kaçmaz F, İlkay E. Clinical approach and emerging therapies for elevated lipoprotein(a): current evidence and guideline-based recommendations. J Cardiol Cardiovasc Surg. 2025;3(4):82-86.

Read: 44
Download : 57
Cited: 0
_Footer